Xie L. Xu

TL;DR: Guselkumab demonstrated a favourable benefit-risk profile and might be an effective treatment option for patients with active psoriatic arthritis.

TL;DR: Guselkumab, a human monoclonal antibody that specifically inhibits IL-23 by binding the cytokine's p19 subunit, was efficacious and demonstrated an acceptable benefit-risk profile in patients with active psoriatic arthritis who were naive to treatment with biologics.

TL;DR: Findings suggest H4R‐antagonism may be beneficial for AD, particularly in controlling pruritus, and may be associated with drug‐induced agranulocytosis, likely an off‐target effect.

TL;DR: JNJ-39758979 is a potent and selective H4R antagonist that exhibited good preclinical and phase 1 safety in healthy volunteers with evidence of a pharmacodynamics effect in humans with excellent selectivity versus other targets.

TL;DR: Patients with active psoriatic arthritis and imaging-confirmed sacroiliitis who were treated with guselkumab every 4 weeks or every 8 weeks had greater mean improvements in BASDAI and ASDAS than did placebo-treated participants, with sustained improvements at week 52.